Intellia Therapeutics Inc (NASDAQ:NTLA) shares traded down 4.8% on Tuesday . The stock traded as low as $17.56 and last traded at $17.67, with a volume of 76,982 shares traded. The stock had previously closed at $18.56.

Several research analysts recently weighed in on the stock. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price objective on the stock. Wedbush started coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price target on the stock. Credit Suisse Group AG started coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price target on the stock. Finally, Jefferies Group started coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price target on the stock.

The firm’s market cap is $646.13 million. The company’s 50-day moving average price is $21.57 and its 200 day moving average price is $23.87.

In related news, Director Carl L. Gordon acquired 250,000 shares of the stock in a transaction dated Wednesday, May 11th. The shares were purchased at an average cost of $18.00 per share, with a total value of $4,500,000.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of the stock in a transaction dated Wednesday, May 11th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.